The company expects net product revenues from sales of zynlonta to be approximately $15.8M for the third quarter ended September 30, with cash and cash equivalents totaling $234.7M as of September 30, 2025. Giving effect to the estimated net proceeds from the PIPE financing of approximately $57.6M, the company would have had approximately $292.3M of cash and cash equivalents as of that date.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT: